Azacitidine and Lenalidomide for Relapsed and Refractory Patients With Acute Myeloid Leukemia
Status:
Completed
Trial end date:
2016-08-03
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to determine the complete remission/complete remission
with incomplete recovery of blood counts (CR/CRi) rate for relapsed and refractory acute
myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) patients.